Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction of GSK3640254 and TAF/FTC in Healthy Subjects
NCT03836729Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Feb 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fipravirimat in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State of TAF, Maximum Observed Concentration of TAF and 6 more. Started Feb 2019; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03836729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836729.